German Other Utilities Stock News

Deutsche Telekom (XTRA:DTE) is taking a prominent role in the expanding EMEA tech sponsorship market alongside other major brands. The company is committing resources to sponsorships and partnerships that focus on digital experiences, VR, and 5G-related technology. These activities place Deutsche Telekom at the center of brand and technology collaborations across the region. For readers tracking telecoms, Deutsche Telekom sits at the intersection of connectivity, media, and entertainment,...

Siltronic (XTRA:WAF) has drawn fresh attention after announcing a private placement of 2,100,000 shares at €89.35 each, raising €187,635,000 and reaffirming Wacker Chemie AG as the largest shareholder at about 24%. See our latest analysis for Siltronic. The private placement headlines coincide with strong momentum in the stock, with a 30 day share price return of 39.6% and a year to date share price return of 105.29%. The 1 year total shareholder return stands at 189.23%, signalling that...

Eckert & Ziegler (XTRA:EUZ) is back in focus after signing a collaboration and supply agreement with Thor Medical ASA, centered on lead-212 based radiopharmaceutical therapies and future production scale up. See our latest analysis for Eckert & Ziegler. The collaboration news arrives after a strong near-term run, with a 9.99% 7-day share price return and a 10.50% 30-day share price return. Over a longer horizon, the 1-year total shareholder return is down 19.19%, while the 3-year total...

Mercedes-Benz Group stock: performance snapshot after recent moves Recent trading in Mercedes-Benz Group (XTRA:MBG) has drawn attention after a mixed stretch, with the stock up about 7% over the past month but down roughly 12% over the past 3 months. See our latest analysis for Mercedes-Benz Group. At a share price of €52.19, Mercedes-Benz Group’s recent 7.05% 1 month share price return contrasts with a weaker 90 day share price return. The 1 year total shareholder return of 6.19% points to...

Q1 2026 earnings snapshot for Ernst Russ (XTRA:ERAG) Ernst Russ (XTRA:ERAG) has opened 2026 with Q1 revenue of €41.0 million and net income of €11.0 million, setting a fresh reference point for investors watching the stock at around €9.10. The company has seen quarterly revenue move from €74.2 million in Q1 2025 to €41.0 million in Q1 2026, while trailing twelve month net income sits at €59.8 million against €42.5 million two years ago. This gives helpful context for how the latest quarter...

Novem Group (XTRA:NVM) closed FY 2026 with fourth quarter revenue of €144.4 million and a net loss of €6.1 million, setting a mixed tone for the latest earnings snapshot. Over recent periods the company has seen quarterly revenue move from €137.964 million in Q4 2025 to €128.9 million in Q1 2026, €125.576 million in Q2 2026, €117.9 million in Q3 2026 and then €144.4 million in Q4 2026. EPS shifted from €0.050251 in Q4 2025 to €0.36 in Q1 2026, €0.063987 in Q2 2026 and a loss of €0.02 in Q3...

Deutsche Bank (XTRA:DBK) stock has been drawing attention after recent trading showed a mixed picture, with the price around €27.86 and returns varying between the past month, past 3 months, and year to date. See our latest analysis for Deutsche Bank. Short term, Deutsche Bank’s 1 day and 7 day share price returns both declined, while its 30 day share price return rose 3.97%. Longer term, total shareholder returns over 1, 3 and 5 years have been strong, suggesting momentum has cooled recently...

Adidas (XTRA:ADS) is teaming up with Simon for a summer-long series of large-scale soccer fan events across major U.S. retail centers. The partnership will feature immersive soccer experiences, exclusive product activations, and limited-edition merchandise aligned with major global soccer events. Fans can expect interactive zones and enhanced in-store experiences at key Simon destinations throughout the summer. For investors watching XTRA:ADS, this move highlights how adidas is leaning into...

Bayer plans to present 16 oncology abstracts at the 2026 ASCO Annual Meeting. Primary results from multiple cancer trials, including several Phase II studies, are set to be shared. The company will reveal head to head data from the Phase II ARACOG (AFT-47) trial of NUBEQA versus enzalutamide in advanced prostate cancer. Additional safety, efficacy, and subgroup analyses will cover a range of Bayer cancer therapies. Bayer (XTRA:BAYN), trading at around €36.53, has had mixed share...

SAP (XTRA:SAP) is back in focus after Sapphire 2026, where the company outlined its Autonomous Enterprise vision and launched its Business AI Platform, supported by partner endorsements and fresh recognition for SAP Signavio. See our latest analysis for SAP. The recent Autonomous Enterprise announcements and partner wins around SAP’s Business AI Platform have coincided with a 1-month share price return of 6.24%. However, the stock is still down 23.26% year to date and the 1-year total...

CTS Eventim KGaA (XTRA:EVD) opened Q1 2026 with revenue of €613.5 million and basic EPS of €0.66, giving investors a fresh look at how its ticketing and live events engine is translating into earnings. The company reported revenue of €498.6 million in Q1 2025 and €613.5 million in Q1 2026, while basic EPS increased from €0.48 to €0.66 over the same period. This frames a quarter where profitability signals appear alongside easing net margins over the last year. See our full analysis for CTS...

Infineon Technologies stock: recent moves catch investors’ attention Infineon Technologies (XTRA:IFX) has drawn fresh interest after a strong recent run in its share price, with the stock up 4.4% over the past day and 17.8% over the past week. That momentum extends further, with gains of 51.7% over the past month and 74.8% over the past 3 months. This has prompted many investors to reassess what is currently priced into the €103.3b semiconductor company. See our latest analysis for Infineon...

Interest in Siemens Healthineers (XTRA:SHL) has picked up after AiM Medical Robotics announced a collaboration that links its MRI-compatible neurosurgery robot with Siemens Healthineers’ MAGNETOM MRI scanners for real-time, image-guided procedures. See our latest analysis for Siemens Healthineers. Despite the robotics collaboration and recent investor outreach, including a UBS roadshow and portfolio review in India, Siemens Healthineers’ share price has been weak, with a year to date share...

Investors may be considering whether Bayerische Motoren Werke stock offers good value at today's price, or if the market is already fully reflecting its current story. The share price closed at €75.94, with a 7 day gain of 2.1%, but is down 4.3% over the past month and 21.2% year to date. The 1 year return sits at 2.3% and the 5 year return at 11.9%. These moves sit against a backdrop of ongoing attention on auto manufacturers, including debates about the balance between traditional...

The European market has recently shown a positive trend, with the pan-European STOXX Europe 600 Index climbing by 3.00%, driven by hopes of easing tensions in the Middle East. Amidst this backdrop, investors are increasingly exploring diverse opportunities within the market, including penny stocks. Though often seen as an outdated term, penny stocks still represent a viable investment avenue for those seeking smaller or newer companies with strong financial foundations and growth potential.

Friedrich Vorwerk Group SE ( ETR:VH2 ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is two...

flatexDEGIRO SE ( ETR:FTK ) is about to trade ex-dividend in the next 4 days. Typically, the ex-dividend date is two...

It looks like Deutsche Beteiligungs AG ( ETR:DBAN ) is about to go ex-dividend in the next 4 days. The ex-dividend date...

MPH Health Care (DB:93M1) has just reported its FY 2025 results with first half revenue of €5.5 million and a basic EPS loss of €17.00, setting a cautious tone around top line scale and per share profitability. Over the previous reporting periods, revenue shifted from €84.2 million in the first half of 2024 to a decline of €18.8 million in the second half of 2024. Basic EPS moved from a gain of €17.41 in early 2024 to a loss of €9.92 in late 2024 and then a deeper loss in the latest half,...

Uber has made an indicative cash offer to acquire Delivery Hero, which the company rejected. Reports suggest Uber is preparing a higher bid and has built a 19.5% stake in Delivery Hero. Delivery Hero's board is reviewing options that include a full sale or divestitures of core regions. Regulatory and antitrust scrutiny are emerging as key considerations for any potential transaction. Delivery Hero (XTRA:DHER) sits at the center of a fast evolving M&A story, with Uber moving from suitor to...

If you are wondering whether SAP at €151.80 offers value or risk at this point in the cycle, this article breaks down what the current price might be implying about the stock. The share price is broadly flat in the near term, with SAP up 0.6% over the past week and 2.0% over the past month. However, the stock is still down 24.8% year to date and down 41.2% over the past year, which may change how you think about its risk and return trade off. These moves sit against a backdrop of ongoing...

IVU Traffic Technologies (XTRA:IVU) has opened 2026 with Q1 revenue of €35.0 million and basic EPS of €0.063, alongside trailing 12 month revenue of €155.2 million and EPS of €0.821 that frame the latest quarter in a broader earnings context. The company has seen quarterly revenue move from €30.8 million in Q1 2025 to €35.0 million in Q1 2026, while basic EPS moved from €0.009 to €0.063 over the same period. This sets up a results season where the key question is how durable these earnings...

PVA TePla (XTRA:TPE) opened Q1 2026 with revenue of €54.9 million and a basic EPS loss of €0.10, as net income excluding extra items came in at a loss of €2.1 million. Over recent quarters the company has seen revenue move between €58.8 million and €71.8 million with basic EPS ranging from a €0.001 loss to €0.42. On a trailing 12-month view, this translates to revenue of €240.3 million and basic EPS of €0.10, setting up a picture where growth expectations are running against currently...

Earlier this month, Bayer announced that the U.S. FDA accepted a supplemental New Drug Application and granted Priority Review for Kerendia (finerenone) in adults with type 1 diabetes and chronic kidney disease, supported by Phase III FINE-ONE data showing significant reduction in urine albumin-to-creatinine ratio over six months alongside standard care. This move could broaden Kerendia’s use beyond its existing approvals in chronic kidney disease linked to type 2 diabetes and heart failure...